As the rich world's govern-ments struggle to contain the costs of health care, they are starting to scrutinise the price of drugs. This may seem unfair, when pharmaceuticals account for less than a fifth of their countries' health-care costs, and mis-rnguided, because innovation will wither if not rewarded. However, a noisy chorus argues that the drug industry is making the prices of its products needlessly high by suppressing cheap generics. Governments from Canada to Japan are looking into this. And, in this case at least, the critics are on to something.
展开▼
